Mymetics 's HIV vacc in late preclinical trials
Mymetics Corp of the USA has been given the green light to commence advanced preclinical testing of its trimeric gp41 vaccine for HIV in nonhuman primates by the US National Institute of Allergy and Infectious Diseases division of the National Institutes of Health.
The study will run through the end of the third quarter of 2005, evaluating the second generation of HIV vaccines in development, the company said. Based on the results of the trial, Mymetics expects to begin advanced toxicology testing by the end of next year in with a view to filing an Investigational New Drug application in 2006, it noted.
Commenting on the firm's development strategy, chief executive Christian Rochet stated that the group "anticipates signing in 2005 a partnership agreement with a major health sciences company to assist us in human clinical trials, for which we plan to file by 2006, pending the results of our preclinical program."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze